4.7 Article

Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome

期刊

JOURNAL OF NEUROSCIENCE
卷 30, 期 29, 页码 9929-9938

出版社

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1714-10.2010

关键词

-

资金

  1. US National Institute on Drug Abuse [DA020140]
  2. US National Institute of Neurological Disorders and Stroke [NS053719]
  3. Hazeltine Foundation
  4. Neurodevelopmental Disorders Fund
  5. Cellular Imaging Core of Intellectual and Developmental Disabilities Research Center [P30HD40677]
  6. FRAXA Research Foundation
  7. Autism Speaks
  8. Epilepsy Foundation
  9. Canadian Institutes of Health Research [181393]

向作者/读者索取更多资源

FragileXsyndrome (FXS) is a neurodevelopmental disorder characterized by variable cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and gaze avoidance. Consistent with this, findings from human brain imaging studies suggest dysfunction of the amygdala. Underlying alterations in amygdala synaptic function in the Fmr1 knock-out (KO) mouse model of FXS, however, remain largely unexplored. Utilizing a combination of approaches, we uncover profound alterations in inhibitory neurotransmission in the amygdala of Fmr1 KO mice. We demonstrate a dramatic reduction in the frequency and amplitude of phasic IPSCs, tonic inhibitory currents, as well as in the number of inhibitory synapses in Fmr1 KO mice. Furthermore, we observe significant alterations in GABA availability, both intracellularly and at the synaptic cleft. Together, these findings identify abnormalities in basal and action potential-dependent inhibitory neurotransmission. Additionally, we reveal a significant neuronal hyperexcitability in principal neurons of the amygdala in Fmr1 KO mice, which is strikingly rescued by pharmacological augmentation of tonic inhibitory tone using the GABA agonist gaboxadol (THIP). Thus, our study reveals relevant inhibitory synaptic abnormalities in the amygdala in the Fmr1 KO brain and supports the notion that pharmacological approaches targeting the GABAergic system may be a viable therapeutic approach toward correcting amygdala-based symptoms in FXS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据